Red Orbit, June 16, 2008 VaxInnate Corporation will discuss its proprietary technology for producing seasonal and pandemic influenza vaccines during BIO 2008 in Atlanta this week. Results of a Phase I study of VaxInnate's M2e universal vaccine candidate will be available this summer. The Phase I study was supported by a $9.5 million grant awarded to UTMB by the Bill & Melinda Gates Foundation for better control of influenza epidemics in the developing world.